Neuromuscular complications in uremics: A review

Neurologist

Volumn 13, Issue 4, 2007, Pages 188-196

  Al Hayk, Kefah ^a   Bertorini, Tulio E ^a,b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Myopathy; Neuropathy; Uremia

Indexed keywords

CARNITINE; CARNITINE PALMITOYLTRANSFERASE; IRON; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; VITAMIN D; ZINC;

ANEMIA; ARTERIOVENOUS SHUNT; ARTERY STEAL SYNDROME; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; COMPRESSIVE NEUROPATHY; DEMYELINATION; DOPPLER FLOWMETRY; DYSESTHESIA; ELECTROMYOGRAPHY; FISTULOGRAPHY; FLOW MEASUREMENT; HUMAN; ISCHEMIC MONOMELIC NEUROPATHY; KIDNEY TRANSPLANTATION; MONONEUROPATHY; MUSCLE BIOPSY; MUSCLE CRAMP; MYASTHENIA LIKE SYNDROME; MYOPATHY; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NEUROMUSCULAR DISEASE; NEUROPATHY; NONHUMAN; OXIMETRY; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; RESTLESS LEGS SYNDROME; REVIEW; SECONDARY HYPERPARATHYROIDISM; SENSORY DYSFUNCTION; UREMIC MYOPATHY; UREMIC POLYNEUROPATHY;

HUMANS; MUSCULAR ATROPHY; NEUROMUSCULAR DISEASES; POLYNEUROPATHIES; UREMIA;

EID: 34447328464     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000263699.53969.e9     Document Type: Review

References (81)

1. Lockwood AH. Neurologic complications of renal disease. Neurol Clin. 1989;7:617-627.
2. Ropper AH. Accelerated neuropathy of renal failure. Arch Neurol. 1993;50:536-539.
3. Yosipovitch G, Yarnitsky D, Mermelstein V, et al. Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve. 1995;18:768-771.
4. Jurcic D, Bago J, Eljunga D, et al. Features of uremic neuropathy in longer-term dialysis. Coll Antropol. 1998;22:119-125.
5. Appenzeller O, Kornfeld M, MacGee J. Neuropathy in chronic renal disease. A Microscopic, ultrastructural, and biochemical study of sural nerve biopsies. Arch Neurol. 1971;24:449-461.
6. Dyck PJ, Johnson WJ, Lambert EH, et al. Segmental demyelination secondary to axonal degeneration in uremic neuropathy. Mayo Clin Proc. 1971;46:400-431.
7. Lascelles RG, Thomas PK. Changes due to age in internodal length in the sural nerve in man. J Neurol Neurosurg Psychiatry. 1966;29:40-44.
8. do Prado LB, do Prado GF, Oliveira AS, et al. Histochemical study of the skeletal muscle in children with chronic renal failure in dialysis treatment. Arq Neuropsiquiatr. 1998;56381-387.
9. Savazzi GM, Buzio C, Migone L. Lights and shadows on the pathogenesis of uremic polyneuropathy. Clin Nephrol. 1982;18:219 -229.
10. Bazzi C, Pagani C, Sorgato G, et al. Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients. Clin Nephrol. 1991;35176-181.
11. Laaksonen S, Matsarinne K, Voipio-Pulkki LM, et al. Neurophysiologic parameters and symptoms in chronic renal failure. Muscle Nerve. 2002;25:884-890.
12. Mansouri B, Adybeig B, Rayegani M, et al. Uremic neuropathy and the analysis of electrophysiological changes. Electromyogr Clin Neurophysiol. 2001;41:107-115.
13. Zakrewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR). Neurophysiol Clin. 2001;31:181-193.
14. Bolton CF, Remtulla H, Toth B, et al. Distinctive electrophysiological features of denervated muscle in uremic patients. J Clin Neurophysiol. 1997;14:539-542.
15. Nielsen VK. The peripheral nerve function in chronic renal failure. VI. The relationship between sensory and motor nerve conduction and kidney function, azotemia, age, sex, and clinical neuropathy. Acta Med Scand. 1973;194:455-462.
16. Babb AL, Ahmad S, Bergstrom J, et al. The middle molecule hypothesis in perspective. Am J Kidney Dis. 1981;1:46-50.
17. Man NK, Terlain B, Paris J, et al. An approach to "middle molecules" identification in artifical kidney dialysate, with reference to neuropathy prevention. Trans Am Soc Artif Intern Organs. 19:320-324.
18. Quellhorst E, Doht B, Schuenemann B. Hemofiltration: treatment of renal failure by ultrafiltration and substitution. J Dial. 1977;1:529-543.
19. Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve. 2007;35:273-290.
20. DiGiulio S, Chkoff N, Lhoste F, et al. Parathormone as a nerve poison in uremia. N Engl J Med. 1978;299:1134-1135.
21. 6 deficiency in uremia and its implications for the depression of immune responses. Kidney Int. 1974;5:233-239.
22. Rossini PM, Marchionno L, Gambi D, et al. EMG changes in chronically dialyzed uremic subjects undergoing d,1-C treatment. Ital J Neurol Sci. 1981;2:255-262.
23. Pirzada NA, Morgenlander JC. Peripheral neuropathy in patients with chronic renal failure. A treatable source of discomfort and disability. Postgrad Med. 1997;102:249-250, 255-257, 261.
24. Sprenger KB, Bundschu D, Lewis K, et al. Improvement of uremic neuropathy and hypogeusia by dialysate zinc supplementation: a doubleblind study. Kidney Int Suppl. 1983;16:S315-S318.
25. Leaksonen S, Voipio-Pulkki L, Erkinjuntti M, et al. Does dialysis therapy improve autonomic and peripheral nervous system abnormalities in chronic uremia? J Intern Med. 2000;248:21-26.
26. Bolton CF. Electrophysiologic changes in uremic neuropathy after successful renal transplantation. Neurology. 1976;26:152-161.
27. Bolton CF, Baltzan MA, Baltzan RB. Effects of renal tansplantation on uremic neuropathy. A clinical and electrophysiologic study. N Engl J Med. 1971;17:284:1170-1175.
28. Mendell JR, Sahenk Z. Clinical practice: painful sensory neuropathy. N Engl J Med. 2003;348:1243-1255.
29. Wolfe GI, Barohn RJ. Painful peripheral neuropathy. Curr Treat Options Neurol. 2002;4:177-188.
30. Wilbourn AJ, Furlan AJ, Hulley W, et al. Ischemic monomelic neuropathy. Neurology. 1983;33:447-451.
31. Kaku DA, Malamut RI, Frey DJ, et al. Conduction block as an early sign of reversible injury in ischemic monomelic neuropathy. Neurology. 1993;43:1126-1130.
32. Riggs JE, Moss AH, Lobosky DA, et al. Upper extremity ischemic monomelic neuropathy: a complication of vascular access procedures in uremic diabetic patients. Neurology. 1989;39:997-998.
33. Bolton CF, Driedger AA, Lindsay RM. Ischemic neuropathy in uremic patients caused by bovine arteriovenous shunt. J Neurol Neurosurg Psychiatry. 1979;42:810-814.
34. Hebl JR, Horlocker TT. Brachial neuropathy after hemodialysis shunt placement under axillary blockade. Anesth Analg. 1999;89:1025-1026.
35. Hye RJ, Wolf YG. Ischemic monomelic neuropathy: an under-recognized complication of hemodialysis access. Ann Vasc Surg. 1994;8:578-582.
36. Wytrzes L, Markley HG, Fisher M, et al. Brachial neuropathy after brachial artery-antecubital vein shunts for chronic hemodialysis. Neurology. 1987;37:1398-1400.
37. Miles AM. Vascular steal syndrome and ischemic monomelic neuropathy: two variants of upper limb ischemia after hemodialysis vascular access surgery. Nephrol Dial Transplant. 1999;14:297-300.
38. Miles AM. Upper limb ischemia after vascular access surgery: differential diagnosis and management. Semin Dial. 2000;13:312-315.
39. Delmez JA, Holtmann B, Sicard GA, et al. Peripheral nerve entrapment syndromes in chronic hemodialysis patients. Nephron. 1982;30:118-123.
40. Goldstein LJ, Helfend LK, Kordestani RK. Postoperative edema after vascular access causing nerve compression secondary to the presence of a perineuronal lipoma: case report. Neurosurgery. 2002;50:412-413; discussion 414.
41. Gilbert MS, Robinson A, Baez A, et al. Carpal tunnel syndrome in patients who are receiving long term renal hemodialysis. J Bone Joint Surg Am. 1988;70:1145-1153.
42. Naito M, Ogata K, Goya T. Carpal tunnel syndrome in chronic renal dialysis patients: clinical evaluation of 62 hands and results of operative treatment. J Hand Surg [Br]. 1987;12:366-374.
43. Schwarz A, Keller F, Seyfert S, et al. Carpal tunnel syndrome: a major complication in long-term hemodialysis patients. Clin Nephrol. 1984;22:133-137.
44. Charra B, Calemard E, Laurent G. Chronic renal failure treatment duration and mode: their relevance to the late dialysis periarticular syndrome. Blood Purif. 1988;6:117-124.
45. Kessler M, Hestin D, Aymard B, et al. Carpal-tunnel syndrome with beta-2-microglobulin amyloid deposits and erosive arthropathy of the wrist and spine in a uremic patient before chronic hemodialysis. Nephrol Dial Transplant. 1995;10:298-299.
46. Kurer MH, Baillod RA, Madgwick JC. Amyloidosis and other musculoskeletal complications of longer-term regular hemodialysis. Br J Hosp Med. 1991;45:266,268-269,271-273.
47. Kurer MH, Baillod RA, Madgwick JC. Musculoskeletal manifestations of amyloidosis. A review of 83 patients on hemodialysis for at least 10 years. J Bone Joint Surg Br. 1991;73:271-276.
48. Ritz E, Bomer J. Beta-2-microglobulin-derived amyloid-problems and perspectives. Blood Purif. 1988;6:61-68.
49. Niwa T. Dialysis-related amyloidosis: pathogenesis focusing on AGE modification. Semin Dial. 2001;14:123-126.
50. Hauglustaine D, Waer M, Michielsen P, et al. Hemodialysis membranes, serum beta-2-microglobulin, and dialysis amyloidosis. Lancet. 1986;1:1211-1212.
51. Casey TT, Stone WJ, DiRaimondo CR, et al. Tumoral amyloidosis of bone of beta-2-microglobulin origin in association with long-term hemodialysis: a new type of amyloid disease. Hum Pathol. 1986;17:731-738.
52. Vaziri ND, Barnes J, Khosrow M, et al. Compression neuropathy subsequent to renal transplantation. Urology. 1976;7:145-147.
53. Ravid M, Robson M. Proximal myopathy caused by latrogenic phosphate depletion. JAMA. 1976;236:1380-1381.
54. Lazaro RP, Kirshner HS. Proximal muscle weakness in uremia: case reports and review of the literature. Arch Neurol. 1980;37:555-558.
55. Floyd M, Ayyar DR, Barwick DD, et al. Myopathy in chronic renal failure. Q J Med. 1974;43:509-524.
56. Quintanilla AP, Sahgal V. Uremic myopathy. Int J Artif Organs. 1984;7:239-242.
57. Zumrutdal A, Bakinen O, Ucan H, et al. Relationship between uremic myopathy and false-positive cardiac troponin T test. Nephron. 2000;86:522-523.
58. Bregman H, Gelfand MC, Winchester JF, et al. HLA-linked iron overload and myopathy in maintenance hemodialysis patients. Trans Am Soc Artif Intern Organs. 1980;26:366-368.
59. Marsden SN, Parkinson IS, Ward MK, et al. Evidence for aluminum accumulation in renal failure. Proc Eur Dial Transplant Assoc. 1979;16:588-596.
60. Thompson CH, Irish AB, Kemp GJ, et al. The effect of propionyl L-carnitine on skeletal muscle metabolism in renal failure. Clin Nephrol. 1977;47:372-378.
61. Wanic-Kossowska M, Grzegorzewska A, Plotast H, et al. Does calcitriol therapy improve muscle function in uremic patients. Perit Dial Int. 1996;16(Suppl 1):S305-S308.
62. Wanner C, Forstner-Wanner S, Rossle C, et al. Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation. Kidney Int Suppl. 1987;22:S132-S135.
63. Ward MK, Feest TG, Ellis HA, et al. Osteomalacic dialysis osteodystrophy: evidence for a water-borne etiological agent, probably aluminum. Lancet. 1978;1:841-845.
64. Baczynski R, Massry SG, Magott M, et al. Effect of parathyroid hormone on energy metabolism of skeletal muscle. Kidney Int. 1985;28:722-727.
65. Smogorzewski M, Piskorska G, Borum PR, et al. Chronic renal failure, parathyroid hormone and fatty acids oxidation in skeletal muscle. Kidney Int. 1988;33:555-560.
66. Lennon DL, Shrago E, Madden M, et al. Carnitine status, plasma lipid profiles and exercise capacity of dialysis patients: effects of a submaximal exercise program. Metabolism. 1986;35:728-735.
67. Bellinghieri G, Domenico S, Calvani M, et al. Carnitine and hemodialysis. Am J Kidney Dis. 2003;41:S116-S122.
68. Bohmer T, Bergrem H, Eiklid K. Carnitine deficiency induced during intermittent hemodialysis for renal failure. Lancet. 1978;1:126-128.
69. Wanner C, Horl WH. Potential role of carnitine in patients with renal insufficiency. Klin Wochenschr. 1986;1:64:579-586.
70. Wanner C, Wieland H, Wackerle B, et al. Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients. Kidney Int Suppl. 1989;27:S264-S268.
71. Spagnoli LG, Palmieri G, Mauiello A, et al. Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle. Nephron. 1990;55:16-23.
72. Nilsson-Ehle P, Cederblad G, Fagher B, et al. Plasma lipoproteins, liver function and glucose metabolism in hemodialysis patients: lack of effect of L-carnitine supplementation. Scand J Clin Lab Invest. 1985;45:179-184.
73. Hodsman AB, Sherrard DJ, Wong EG, et al. Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Ann Intern Med. 1981;94:629-637.
74. Pierides AM. Dialysis dementia, osteomalacia fractures and myopathy: a syndrome due to chronic aluminum intoxication. Int J Artif Organs. 1978;1:206-208.
75. Nangaku M, Miyata T, Kurokawa K. Pathogenesis and management of dialysis-related amyloid bone disease. Am J Med Sci. 1999;317:410-415.
76. Levin JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve. 2004;30:569-577.
77. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:786-790.
78. Quan TE, Cowper S, WuSP, et al. Circulating fibrocytes:collagen-secreting cells of the peripheral blood. Int J Biochem Cell. Biol. 2004;36:598-606.
79. Campistol JM. Uremic myopathy. Kidney Int. 2002;62:1901-1913.
80. DeGrandis D, Mezzina C, Fiaschi A, et al. Myasthenia due to carnitine treatment. J Neurol Sci. 1980;46:365-371.
81. Niakan E, Bertorini TE, Acchiardo SR, et al. Procainamide-induced myasthenia-like weakness in a patient with peripheral neuropathy. Arch Neurol. 1981;38:378-379.